A Phase-II Study with Idarubicin, Ifosfamide and VP-16 (IIVP-16) in Patients with Refractory or Relapsed Aggressive and High Grade non-Hodgkin's Lymphoma
| Autor: | Martin Wilhelm, B. Dederichs, M. Engelhard, Roland Schnell, M. E. Scheulen, S. Baltes-Engler, Hans Tesch, Volker Diehl, Bernhard Wörmann, F. Kupper, B. Lathan, B. Winterhalter, Marcel Reiser, Andreas Engert |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Daunorubicin Individuality Gastroenterology hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Idarubicin Ifosfamide Etoposide Aged Leukopenia business.industry Lymphoma Non-Hodgkin Hematology Middle Aged medicine.disease Lymphoma Non-Hodgkin's lymphoma Regimen Oncology Female medicine.symptom business medicine.drug |
| Zdroj: | Leukemia & Lymphoma. 24:513-522 |
| ISSN: | 1029-2403 1042-8194 |
| Popis: | We report a phase-II study of idarubicin, ifosphamide and etoposide (IIVP-16) in heavily pretreated patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. The IIVP-16 regimen consisted of idarubicin (10 mg/m2 i.v. days 1 + 2 or days 1 + 8), ifosfamide (1000 mg/m2 i.v. days 1-5) and VP-16 (150 mg/m2 i.v. days 103). 40 patients were enrolled. Of 38 evaluable patients, 26 had centroblastic subtype, followed by lymphoblastic (6), immunoblastic (2), and other entities (4). 18 patients were primary resistant; 14 patients had early relapse (CR less than 12 months) and 8 patients late relapse (CR longer than 12 months). The median number of different prior chemotherapy regimens was 2 (range 1 to 6). 20 patients had received additional radiotherapy. The response-rate was 47.4% including 8 CR (21.1%) and 10 PR (26.3%). IIVP-16 was more effective in patients with relapsed disease when compared with patients with primary resistant disease (response rate 65% vs. 27.8%, p0.025). Leukopenia and thrombocytopenia were the major toxicities occurring in 73/107 (68.2%) and 57/107 (53.3%) of cycles (WHO grade IV). IIVP-16 is an effective regimen particularly in patients with unfavorable relapsed NHL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|